MIT

Universities Allied for Essential Medicines

PIH/David Walton

•

You bring kindness, and your kindness is good. But it will not cure this AIDS.

•

I know there is medicine in your country for people like you. But why not here, for people like me?

Pharmaceutical industry expenditures

Worldwide, 1996-2005

25% Profits

32% Marketing and administration 30% Operational and material costs 12% R&D

Drs. Prusoff and Lin at Yale discovered that d4t (stavudine, Zerit) is active against HIV. D4t became a key first-line antiretroviral.

Because Yale licensed d4t exclusively to Bristol Myers Squibb, the company set a monopoly price (too high for poor patients)

Flickr/MikeBlyth

Impact of Generic Competition: Uganda

Magnum Photos/Francesco Zizola

In South Africa, MSF and the Treatment Action Campaign bought low-price, generic d4t to save the lives of the HIV+ poor.

The generic d4t was technically illegal, because it infringed on Bristol Myers Squibb’s patent on d4t in South Africa.

Antiretroviral treatment can literally bring a dying patient back After six months on ARV therapy

PIH/David Walton

Bristol Myers Squibb launched a lawsuit for patent infringement against the South African generic company, essentially asserting that

it is acceptable to die of a treatable infection so long as you are poor enough.

“The Scientist’s Story”

“I once helped create a drug that could enable millions of people to lead better and longer lives…More recently, it became apparent that the drug Dr. Lin and I had developed was not reaching millions of desperately suffering people because they lacked the money to purchase it.” NYTimes Editorial: March 19, 2001 By William Prusoff.

Role of Academic Research

 Academic patents in 1 in every 5 of the most innovative Rx (FDA priority review)  Academic patents in 1 in every 4 HIV Rx.

 In 44% of cases, universities filed for patent protection in developing world.

Sampat, Am J. Pub. H., 2009

PhRMA Sales by Geographic Area

Global Access Licensing

Patent

Gener-X

The New “Scientist’s Story”

• Dr. Kishor M. Wasan

Meeting with Harvard’s President

Just prior to SPS (October 2009)

The Statement of Principles and Strategies for Equitable Dissemination of Medical Technologies (SPS) is Born

Discuss Stakeholder Meeting, Committee on Global Access Licensing with Dean of Public Health Faculty outreach for Working Group on Licensing Provost and TTO Head reveal plans to develop multi university agreement SPS Launched Meeting with Harvard President Yale Provost agrees to articulate policies First meeting with OTD, friendly Yale monthly OTD meetings

Crimson

op-ed exchange Petition to Provost Meeting with OTD and CEOs, unfriendly Multi University Roundtable

Say Yes To Drugs

Campaign

Current Signatories Institution

Association of University Technology Managers Boston Univ Brown Univ Harvard Univ Univ of Pennsylvania Yale Univ Oregon Health & Science University National Institutes of Health University of Illinois Chicago University of Illinois Urbana-Champaign Centers for Disease Control and Prevention University of Vermont and State Agricultural College Duke University and Duke Medicine University of British Columbia Bilkent University El Colegio de México New York University Tecnologico de Monterrey Jawaharlal Nehru University Najit Technologies, Inc.

Brigham & Women's Hospital Florida State University Massachusetts General Hospital

Signing Date

11/9/2009 11/9/2009 11/9/2009 11/9/2009 11/9/2009 11/9/2009 11/9/2009 11/10/2009 11/10/2009 11/11/2009 11/12/2009 11/19/2009 12/1/2009 1/10/2010 1/27/2010 1/27/2010 2/4/2010 2/13/2010 2/18/2010 3/4/2010 3/15/2010 3/29/2010 3/29/2010

Mission Statement

The mission of MIT is to advance knowledge and educate students in science, technology, and other areas of scholarship that will best serve the

nation and the world in the 21st century.

The Institute is committed to generating, disseminating, and preserving knowledge, and to working with others to bring this knowledge to bear on the world's great challenges. MIT is dedicated to providing its students with an education that combines rigorous academic study and the excitement of discovery with the support and intellectual stimulation of a diverse campus community. We seek to develop in each member of the MIT community the ability and passion to work wisely, creatively, and effectively for the betterment of humankind.

Our Vision

Universities and publicly funded research institutions will be part of the solution to the access to medicines crisis by promoting medical innovation in the public interest and ensuring that all people regardless of income have access to essential medicines and other health-related technologies.

Our Mission

As a private non-profit organization rooted in a movement of university students, UAEM aims to - promote access to medicines for people in developing countries by changing norms and practices around university patenting and licensing - ensure that university medical research meets the needs of the majority of the world’s population - empower students to respond to the access and innovation crisis